Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of DirectorsGlobeNewsWire · Oct 1, 2026
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 2, 2026
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing ObligationGlobeNewsWire · Aug 31, 2026
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 14, 2026
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 13, 2026Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$3.18 | $2.96 | Beat |
| May 11, 2026 | -$3.36 | -$3.74 | Miss |
| Mar 16, 2026 | -$3.89 | -$3.51 | Beat |
| Nov 10, 2025 | -$4.01 | -$1.61 | Beat |
| Aug 11, 2025 | -$2.25 | -$3.38 | Miss |
| May 12, 2025 | $0.75 | $0.05 | Miss |